1. Home
  2. PMI vs LEXX Comparison

PMI vs LEXX Comparison

Compare PMI & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PMI

Picard Medical Inc.

HOLD

Current Price

$0.15

Market Cap

14.1M

Sector

N/A

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.61

Market Cap

16.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMI
LEXX
Founded
1981
2004
Country
United States
Canada
Employees
75
7
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.1M
16.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PMI
LEXX
Price
$0.15
$0.61
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
6.3M
58.3K
Earning Date
06-18-2026
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.46
52 Week High
$13.68
$1.55

Technical Indicators

Market Signals
Indicator
PMI
LEXX
Relative Strength Index (RSI) 37.92 52.60
Support Level $0.15 $0.57
Resistance Level $0.27 $0.70
Average True Range (ATR) 0.02 0.05
MACD 0.01 0.01
Stochastic Oscillator 18.51 73.83

Price Performance

Historical Comparison
PMI
LEXX

About PMI Picard Medical Inc.

Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: